A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

• Published in: Journal of investigative dermatology Vol. 123; no. 6; pp. 1037 - 1044
• Main Authors: Kauffman, Catharine L., Aria, Nancy, Toichi, Eiko, McCormick, Thomas S., Cooper, Kevin D., Gottlieb, Alice B., Everitt, Daniel E., Frederick, Bart, Zhu, Yaowei, Graham, Martin A., Pendley, Charles E., Mascelli, Mary Ann
• Format: Journal Article
• Language: English
• Published: Danvers, MA Elsevier Inc 01.12.2004; Nature Publishing; Elsevier Limited
• Subjects: Adult; anti-IL-12p40; Biological and medical sciences; Dermatology; Female; Humans; Immunoglobulins, Intravenous - administration & dosage; Immunoglobulins, Intravenous - adverse effects; Immunoglobulins, Intravenous - pharmacokinetics; interleukin-12; Interleukin-12 - immunology; Interleukin-12 Subunit p40; interleukin-23; Male; Medical sciences; Middle Aged; PASI; Protein Subunits - immunology; psoriasis; Psoriasis - immunology; Psoriasis - therapy; Psoriasis. Parapsoriasis. Lichen; Severity of Illness Index; Treatment Outcome; PASI; anti-IL-12p40; psoriasis; interleukin-12; interleukin-23; Human; Skin disease; Psoriasis; Antibody; Dermatology; Toxicity; Cytokine; Interleukin 12; Interleukin 23; anti-IL-12p40/interleukin-12/interleukin-23/PASI/psoriasis; Treatment; Phase I trial; Safety; Pharmacokinetics

The potential therapeutic activity of a human monoclonal antibody to the human interleukin-12 p40 subunit (anti-IL-12p40) has been established both in vitro and in vivo, warranting a first-in-human investigation in psoriasis. This phase I, first-in-human, non-randomized, open-label study evaluated t...